Osteocalcin belongs to the osteocalcin/matrix Gla protein family. It constitutes 1 to 2% of the total bone protein. It is made by osteoblasts, and is a major component of the noncollagenous bone matrix. It has a high affinity for calcium and binds strongly to apatite. Sixty to ninety percent of de novo synthesized osteocalcin is incorporated into the bone matrix where it binds to hydroxyapatite during matrix mineralization. The remainder of the osteocalcin is released into the circulation where it can be measured as a sensitive marker of bone formation. Osteocalcin found in serum is almost exclusively derived from the bone formation with little or no contribution from the resorption process. Drugs acting primarily on bone resorption, such as bisphosphonates, induce a rapid decline in specific bone resorption markers, whereas osteocalcin levels only change after extended therapy periods, in accordance with the expected dynamics of a bone formation marker. Serum osteocalcin is elevated in diseases characterized by increased bone turnover such as osteoporosis, hyperparathyroidism and Paget′s disease, and low in conditions associated with low bone turnover such as hypoparathyroidism and growth hormone deficiency.

The antibody reacts with the osteocalcin protein.

Epitope: aa 59-74

Synthetic peptide corresponding to aa 59-74 of osteocalcin protein.

Detect Osteocalcin using this Anti-Osteocalcin Antibody validated for use in WB, IH.

Routinely evaluated by Western Blot on human heart lysate.

Western Blot Analysis:
1:500 - 1:5,000 dilution of this antibody detected osteocalcin in 10 μg of human heart lysate.

11 kDa calculated.
*Band of ~22 kDa is observed. The difference between observed and expected band may be due to post-translational modifications.

Replaces: MABD182